The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 10, 2024

Filed:

Jul. 31, 2019
Applicant:

Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, CN;

Inventors:

Dajun Yang, Suzhou, CN;

Yifan Zhai, Suzhou, CN;

Guangfeng Wang, Suzhou, CN;

Douglas Dong Fang, Suzhou, CN;

Jing Deng, Suzhou, CN;

Miaozhen Qiu, Suzhou, CN;

Lin Zhang, Suzhou, CN;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/675 (2006.01); A61K 9/00 (2006.01); A61K 31/337 (2006.01); A61K 31/4045 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/513 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/337 (2013.01); A61K 31/4045 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/513 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01);
Abstract

The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.


Find Patent Forward Citations

Loading…